Summary

Cardiopulmonary Exercise Testing Market Research Report Forecast till 2032

Market Overview
Cardiopulmonary Exercise Testing Market is expected to register a healthy CAGR of 7.25% during the forecast period.
The developing pervasiveness of cardiovascular infections like cardiovascular breakdown, and aspiratory hypertension among others across the globe is driving the development of the cardiopulmonary exercise testing market. Cardiopulmonary exercise testing gives important symptomatic data and assists in deciding with practicing limit and utilitarian limits in patients with these circumstances. As per the article distributed by Public Community for Biotechnology Data in June 2022, the test can give both cardiovascular and pneumonic sickness processes, while helping with the advancement of individualized treatment and recovery programs. Also, the rising commonness of cardiovascular sicknesses can be credited to different variables, including maturing populaces, stationary ways of life, smoking, air contamination, and unfortunate eating regimens. As these illnesses progress, they lead to practical impediments, diminished exercise resilience, and hindered cardiopulmonary wellness. In this specific circumstance.
The geriatric populace is more inclined to ongoing infections and grown-ups matured 65 and more seasoned are more probable than more youthful individuals to experience the ill effects of cardiovascular sickness. Maturing can likewise cause a gamble of creating cardiovascular infection. Hence, the rising populace of this part of individuals can likewise build the interest for cardiopulmonary exercise testing to survey a person's cardiovascular and respiratory capabilities.
Accordingly, the developing predominance of cardiovascular illnesses and other constant sicknesses and expanding utilizations of radioisotopes in the medical services industry are energizing market development.
Market Segmentation
The Cardiopulmonary Exercise Testing Market has been divided into two segments based on product type: software and CPET metabolic carts.
The Cardiopulmonary Exercise Testing Market has been divided into ambulatory centers, diagnostic centers, hospitals & clinics, and others based on the end user.
Regional Insights
North America is likely to lead the market owing to a largest market contribution of 37.77% in 2022.
Furthermore, the region's significant development is emphatically impacted by expanding rates of cardiovascular sicknesses (CVD), which increment the interest for cardiopulmonary exercise testing (CPET) programming and CPET metabolic trucks. The CPET metabolic trucks and programming are used in CVDs to offer an assessment of the respiratory, cardiovascular, and skeletal muscle frameworks' coordinated exercise reactions.
The Europe region shows critical development during the forecast time frame. This is because of the rising predominance of persistent sicknesses like cardiovascular illnesses, respiratory problems, and metabolic circumstances that is driving the interest for CPET in Europe. CPET gives important analytic and prognostic data for these circumstances, supporting customized treatment and the board methodologies.
The development of the market in Asia-Pacific is anticipated to rise quickly because of an attributable to high utilizations of CPET in the geriatric populace as maturing populaces are more inclined to CVDs. According to the Asia-Pacific Report on Populace Maturing 2022, there were around 670 million individuals matured 60 or more established in Asia-Pacific in 2022. Besides, the possibilities having CVDs expansion in diabetic patients, which expands the interest for CPET gadgets.
Major Players
Key Companies in the Cardiopulmonary Exercise Testing Market includes Schiller AG, COSMED srl, MGC Diagnostics Corporation, Oxigraf, Inc, Vyaire Medical, Inc, CORTEX Biophysik GmbH, Koninklijke Philips NV, Hill-Rom Holdings, Inc, MEDEV Medical Devices Corporation, Geratherm Medical AG, Schiller AG, COSMED srl, and Others.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASE IN THE PREVALENCE OF CARDIOVASCULAR DISEASES

4.2.2 RISING GERIATRIC POPULATION

4.3 RESTRAINTS

4.3.1 LACK OF SKILLED AND EXPERIENCED PROFESSIONALS

4.4 OPPORTUNITIES

4.4.1 GROWING NUMBER OF STRATEGIC INITIATIVES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D & DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON KEY PLAYERS

5.3.3 IMPACT ON DEMAND

5.4 QUANTITATIVE MARKET INSIGHTS

5.4.1 NUMBER OF CPET METABOLIC CARTS BY REGION, 2022

5.4.2 AVERAGE TESTS PERFORMED IN 2022, BY TYPE OF FACILITIES, BY REGION, 2022

5.5 QUALITATIVE CONSUMER ASSESSMENT

5.5.1 DEMAND FOR CPET SOFTWARE IN MAJOR REGIONS

5.5.2 AVERAGE TIME REQUIRED FOR INTERPRETING CPET TESTS, INCLUDING REPORTING.

5.5.3 % CHANCES OF ADOPTION OF TECHNOLOGICAL ADVANCEMENTS SUCH AS SEMI-AUTOMATIC INTERPRETATION PROGRAM

5.5.4 RANGE OF % PROFITS BY FACILITIES PERFORMING CPET TESTS

5.5.5 % INVESTMENTS IN CPET SOFTWARE

6 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT

6.1 OVERVIEW

6.2 CPET METABOLIC CARTS

6.3 SOFTWARE

7 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY END USER

7.1 OVERVIEW

7.2 HOSPITALS & CLINICS

7.3 DIAGNOSTIC CENTERS

7.4 AMBULATORY CENTERS

7.5 OTHERS

8 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION

8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 GERMANY

8.3.2 FRANCE

8.3.3 UK

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA-PACIFIC

8.4.1 CHINA

8.4.2 INDIA

8.4.3 JAPAN

8.4.4 AUSTRALIA

8.4.5 SOUTH KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 REST OF THE WORLD

8.5.1 MIDDLE EAST

8.5.2 AFRICA

8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET

9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET

9.5 KEY DEVELOPMENT ANALYSIS

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 PRODUCT/COMPANY LAUNCH/PRODUCT APPROVAL

9.6.2 COLLABORATION/AGREEMENT

9.7 FINANCIAL MATRIX

9.7.1 SALES (USD MILLION), 2021

9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

10.1 SCHILLER AG

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 COSMED SRL

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 MGC DIAGNOSTICS CORPORATION

10.3.1 COMPANY OVERVIEWS

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 OXIGRAF, INC

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 KEY STRATEGIES

10.5 VYAIRE MEDICAL, INC

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 CORTEX BIOPHYSIK GMBH

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 KEY STRATEGIES

10.7 KONINKLIJKE PHILIPS N.V.

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 HILL-ROM HOLDINGS, INC

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 MEDEV MEDICAL DEVICES CORPORATION

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 SWOT ANALYSIS

10.9.6 KEY STRATEGIES

10.10 GERATHERM MEDICAL AG

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 SWOT ANALYSIS

10.10.6 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 NUMBER OF CPET METABOLIC CARTS, BY REGION, 2022

TABLE 4 AVERAGE TESTS PERFORMED, BY REGION, 2022

TABLE 5 AVERAGE TIME REQUIRED FOR INTERPRETING CPET TESTS

TABLE 6 RANGE OF % PROFITS BY FACILITIES PERFORMING CPET TESTS

TABLE 7 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 8 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR CPET METABOLIC CARTS, BY REGION, 2019–2030 (USD MILLION)

TABLE 9 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR SOFTWARE, BY REGION, 2019–2030 (USD MILLION)

TABLE 10 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 11 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2019–2030 (USD MILLION)

TABLE 12 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 13 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR AMBULATORY CENTERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 14 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 15 GLOBAL: CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION, 2019–2030 (USD MILLION)

TABLE 16 NORTH AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 17 NORTH AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 18 NORTH AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 19 US: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 20 US: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 21 CANADA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 22 CANADA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 23 EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 24 EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 25 EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 26 GERMANY: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 27 GERMANY: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 28 FRANCE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 29 FRANCE: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 30 UK: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 31 UK: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 32 ITALY: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 33 ITALY: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 34 SPAIN: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 35 SPAIN: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 36 REST OF EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 37 REST OF EUROPE: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 40 ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 41 CHINA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 42 CHINA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 43 INDIA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 44 INDIA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 45 JAPAN: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 46 JAPAN: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 47 AUSTRALIA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 48 AUSTRALIA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 49 SOUTH KOREA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 50 SOUTH KOREA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 51 REST OF ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 52 REST OF ASIA-PACIFIC: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 53 REST OT THE WORLD: CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION, 2019–2030 (USD MILLION)

TABLE 54 REST OT THE WORLD: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 55 REST OT THE WORLD: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 56 MIDDLE EAST: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 57 MIDDLE EAST: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 58 AFRICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 59 AFRICA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 60 LATIN AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT, 2019–2030 (USD MILLION)

TABLE 61 LATIN AMERICA: CARDIOPULMONARY EXERCISE TESTING MARKET BY END USER, 2019–2030 (USD MILLION)

TABLE 62 MAJOR PLAYERS IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET

TABLE 63 MOST ACTIVE PLAYER IN THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET

TABLE 64 PRODUCT/COMPANY LAUNCH/PRODUCT APPROVAL

TABLE 65 COLLABORATION/AGREEMENT

TABLE 66 SCHILLER AG: PRODUCTS OFFERED

TABLE 67 COSMED SRL: PRODUCTS OFFERED

TABLE 68 COSMED SRL: KEY DEVELOPMENTS

TABLE 69 MGC DIAGNOSTICS CORPORATION: PRODUCTS OFFERED

TABLE 70 MGC DIAGNOSTICS CORPORATION: KEY DEVELOPMENTS

TABLE 71 OXIGRAF, INC: PRODUCTS OFFERED

TABLE 72 VYAIRE MEDICAL, INC: PRODUCTS OFFERED

TABLE 73 CORTEX BIOPHYSICS GMBH: PRODUCTS OFFERED

TABLE 74 KONINKLIJKE PHILIPS NV: PRODUCTS OFFERED

TABLE 75 HILL-ROM HOLDINGS, INC: PRODUCTS OFFERED

TABLE 76 MEDEV MEDICAL DEVICES CORPORATION: PRODUCTS OFFERED

TABLE 77 GERATHERM MEDICAL AG: PRODUCTS OFFERED